01Proliferating myoblastMeasured reference0 h human-myogenic reference; no candidate DMD perturbation.
→
02Early differentiationMeasured reference24–48 h trajectory; descriptive, unperturbed context.
→
03FusionLimited perturbation context9 of 21 candidates assessed in a human-myoblast screen; not DMD replication.
→
04Maturing myotubeNot yet tested72 h reference exists; candidate perturbation function is unmeasured.
→
05Damage / stress responseNot yet testedFunctional DMD injury and recovery endpoints remain future study outcomes.
What this means: the current release can locate a question along a real human-myogenic reference, but it cannot simulate a DMD perturbation-conditioned fate.
Open decisions
Three different gaps require three different actions.
Ordered by decision type · not ranked
Decision 01DRAFT NOT REGISTERED
ZNF133 + MON1A myogenic test
Resolve whether ZNF133 or MON1A has a disease-context myogenic effect
Do ZNF133 or MON1A perturbations change a prespecified myogenic functional endpoint differently in DMD and matched-control cells?
What is already known
Observed CRISPRi response exists in HepG2 for ZNF133 (84 cells) and MON1A (94 cells).
Both targets were assessed in the GSE293514 human-myoblast fusion screen and neither met its FDR < 0.1 hit threshold.
Both current candidate records retain source-conflicted DMD direction and recommend a muscle-context assay.
What blocks the decisionNeither target has an independent perturbation repeated in a DMD muscle model.
Next discriminating action
Compare both targets in the same matched DMD/control human-myogenic assay, using qualified independent reagents and one frozen primary functional endpoint.
How would the result change the decision?
A reproducible DMD-specific effect would justify disease-context follow-up.
A similar effect in DMD and control would support a broader myogenic—not DMD-specific—interpretation.
A near-zero result inside a frozen equivalence margin would downgrade the hypothesis.
Viability loss, differentiation blockade or reagent discordance would classify the result as toxic or inconclusive.
Boundary: This card recommends a discriminating experiment. It does not predict that either target will improve DMD.
Determine whether pending external evidence should change the GFOD2 record
Does the author-reported external assessment provide traceable quantitative evidence that survives the released import and audit rules?
What is already known
GFOD2 has an observed HepG2 CRISPRi response with 127 cells in the frozen aggregate.
GFOD2 was not included in the GSE293514 human-myoblast fusion library.
Its historical rank is preserved only for reproducibility; there is no current numeric rank.
What blocks the decisionThe reported external quantitative evidence, source provenance and analysis code have not been imported and audited.
Next discriminating action
Import the external result with source identifiers, quantitative values and analysis provenance, then run the released validation contract before changing status.
How would the result change the decision?
A complete, reproducible import can move the record from provisional hold to computational triage.
An incomplete or incompatible import leaves the record on hold.
Either outcome remains contextual evidence—not DMD perturbation efficacy.
Boundary: Audit resolution can change evidence status but cannot create a muscle, DMD or therapeutic validation claim.
Freeze a balanced 24-slot DMD pilot before any outcome is visible
Which candidate, control and calibration conditions should occupy the 24 pilot slots under rules frozen before outcome access?
What is already known
All 24 Stage A identities are provisionally assigned: 14 candidate genes and 10 calibration controls.
The assignments remain editable; panel signoff and a frozen checksum are still pending.
No study or prediction has been registered, no experiment has started and no outcome has been measured.
What blocks the decisionPanel signoff, one primary endpoint, a minimally important effect and a negligible-effect margin remain unfrozen.
Next discriminating action
Sign off and checksum-freeze the assigned panel, endpoint and decision thresholds, then register an immutable truth-generation Study. Add a Prediction only when a condition is explicitly assigned to prediction validation.
How would the result change the decision?
A frozen panel makes future hit-rate and enrichment claims auditable.
Controls allow calibration of false positives, nulls and toxicity.
Pre-outcome registration prevents retrospective relabelling of successes and failures.
Boundary: This is an assigned but unfrozen prospective design. It contains no registered experiment, measured outcome or efficacy result.
The next milestone is a frozen decision—not another page.
Four of eleven no-new-wet-lab modules are executed or available. All 24 pilot identities are provisionally assigned; panel signoff is pending. Study, prediction and outcome registries await prospective work.